Liraglutide-Induced Hepatotoxicity
Yaakov Maor, David Ergaz, Stephen Malnick, Ehud Melzer, Manuela G. Neuman
Abstract
was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug's mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients.
Topics & Concepts
LiraglutideMedicinePharmacovigilanceDrugPharmacologyIncretinExenatideSaxagliptinIntensive care medicineDiabetes mellitusType 2 diabetesEndocrinologySitagliptinDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDrug Transport and Resistance Mechanisms